Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a 52‐Week, Randomized, Controlled Trial

• Published in: Arthritis care & research (2010) Vol. 74; no. 3; pp. 451 - 460
• Main Authors: Walsh, Jessica A., Magrey, Marina N., Baraliakos, Xenofon, Inui, Kentaro, Weng, Meng‐Yu, Lubrano, Ennio, Heijde, Désirée, Boonen, Annelies, Gensler, Lianne S., Strand, Vibeke, Braun, Jürgen, Hunter, Theresa, Li, Xiaoqi, Zhu, Baojin, León, Luis, Calderon, David Marcelino Sandoval, Kiltz, Uta
• Format: Journal Article
• Language: English
• Published: Boston, USA Wiley Periodicals, Inc 01.03.2022; Wiley Subscription Services, Inc
• Subjects: Adult; Antibodies, Monoclonal, Humanized - administration & dosage; Antirheumatic Agents - administration & dosage; Arthritis; Double-Blind Method; Drug Administration Schedule; Female; Humans; Inflammatory diseases; Male; Middle Aged; Monoclonal antibodies; Non-Radiographic Axial Spondyloarthritis - drug therapy; Original; Patients; Placebos; Quality of Life; Rheumatic diseases; Spondyloarthritis; Treatment Outcome
• ISSN: 2151-464X; 2151-4658
• DOI: 10.1002/acr.24482

Objective To evaluate the effect of ixekizumab on self‐reported functioning and health in patients with active nonradiographic axial spondyloarthritis (SpA). Methods COAST‐X was a randomized, controlled trial conducted in patients with nonradiographic axial SpA over 52 weeks. Participants were randomized at a ratio of 1:1:1 to receive 80 mg of ixekizumab subcutaneously every 4 weeks or 2 weeks or placebo for 52 weeks. Self‐reported functioning and health end points included the Medical Outcomes Study Short Form 36 (SF‐36) health survey, Assessment of Spondyloarthritis International Society (ASAS) health index, and European Quality of Life‐5 Dimensions‐5 Level (EQ‐5D‐5L) health‐utility descriptive system. Results Compared to placebo, ixekizumab treatment resulted in improvement of SF‐36 physical component summary scores from baseline, with a score of 4.7 improving to 8.9 with ixekizumab therapy every 4 weeks (P < 0.05) and a score of 9.3 with ixekizumab therapy every 2 weeks (P < 0.01); the greatest improvements were observed in the domains of physical functioning, role‐physical, and bodily pain at weeks 16 and 52. A higher proportion of patients receiving ixekizumab therapy every 2 weeks reported ≥3 improvements based on the ASAS health index from baseline to weeks 16 and 52 (P < 0.05). Significantly more patients receiving ixekizumab every 4 weeks reported improvements in “good health status” on the ASAS health index (ASAS score of ≤5) at weeks 16 and 52 (P < 0.05). Patients receiving ixekizumab reported improvements on the EQ‐5D‐5L compared to those who received placebo at week 16 (0.11 versus 0.17 for patients receiving treatment every 4 weeks and 0.19 for patients receiving treatment every 2 weeks; P < 0.05), which remained consistent at week 52. There were no clinical meaningful differences in responses based on the ixekizumab dosing regimen for patients who received ixekizumab therapy every 2 weeks or every 4 weeks. Conclusion In patients with nonradiographic axial SpA, therapy with ixekizumab was superior to placebo in the improvement of self‐reported functioning and health at weeks 16 and 52.